Bromide

Bromide

SCHEMBL3145494

[Br-].[H+].c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.32
TDP1 Q9NUW8 3/20 0.86
CYP3A4 P08684 1/20 0.86
ESR1 P03372 4/20 0.60
ESR2 Q92731 4/20 0.60
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 3/20 0.35
DRD1 P21728 2/20 0.34
LMNA P02545 3/20 0.32
MAPT P10636 2/20 0.32
HTT P42858 1/20 0.32
TSHR P16473 4/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA12 O43570 1/20 0.32
GLA P06280 1/20 0.32
CA3 P07451 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4763493 0.97 TDP1 (0.80) TDP1CYP3A4ESR1ESR2KDM4E
SCHEMBL11170638 0.96 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL1776383 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL6387304 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL5167893 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL3156048 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL6392383 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL621886 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL6561245 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Bromide SCHEMBL417857 0.93 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110483448-A A kind of synthetic method of multichiral center gamma lactone class compound UNIV WUYI 2019-11-22 CN claimed
CN-119751392-A Benzofuran compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 南方医科大学 2025-04-04 CN disclosed
EP-3805192-B1 NOVEL BIPHENYL DERIVATIVE COMPOUND AND USE THEREOF UNIV EWHA IND COLLABORATION (KR) 2024-09-11 EP disclosed
CN-115385837-B Method for preparing astaxanthin by oxidation of canthaxanthin 万华化学集团股份有限公司 2024-04-09 CN disclosed
US-11939308-B2 Biphenyl derivative compound and use thereof EWHA University—Industry Collaboration Foundation (KR) 2024-03-26 US disclosed
CN-113527388-B Method for stereoselective synthesis of beta-2-deoxy sugar, 2-deoxy-2-azido sugar and glucosidic bond 中国药科大学 2024-01-26 CN disclosed
CN-112512999-B Novel biphenyl derivative compound and use thereof 梨花女子大学产学协力团 2023-06-13 CN disclosed
CN-111747876-B Method for preparing astaxanthin by oxidizing canthaxanthin 万华化学集团股份有限公司 2023-05-26 CN disclosed
CN-116144192-A Semi-cyanine near infrared two-region dye and preparation method and application thereof 中山大学 2023-05-23 CN disclosed
CN-115385837-A Method for preparing astaxanthin through canthaxanthin oxidation 万华化学集团股份有限公司 2022-11-25 CN disclosed
CN-101842725-A Optical element with optical adhesive layer and polarizer SEIKO EPSON CORP 2010-09-22 CN disclosed
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma ASTRAZENECA AB (SE) 2010-04-01 US disclosed
WO-2009020578-A1 ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION (US) 2009-02-12 WO disclosed
CN-101351448-A Novel 1-benzyl-4-piperidinamines for the treatment of COPD and asthma ASTRAZENECA AB (SE) 2009-01-21 CN disclosed
EP-1945613-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA AstraZeneca AB (SE) 2008-07-23 EP disclosed
WO-2007053082-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA ASTRAZENECA AB (SE) 2007-05-10 WO disclosed
CN-1320599-A Limited 9-cis-isotretinoins AMERICAN CYANAMID CO (US) 2001-11-07 CN disclosed
CN-1176248-A Restricted 9-CIS-retinoids AMERICAN CYANAMID CO (US) 1998-03-18 CN disclosed
CN-1061594-A Hydroxyalkyl quinoline ether acid as leukotriene antagonists MERCK FROSST CANADA INT (CA) 1992-06-03 CN disclosed
US-4605675-A Polyene compounds useful in the treatment of allergic responses USV PHARMACEUTICAL CORP. (US) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939308-B2 Biphenyl derivative compound and use thereof NDC1, NME1, NME4 ACHE 3075/4885TDP1 2872/4885CYP3A4 3385/4885
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma CCR1, CCR4, CCR10 ACHE 3964/4885TDP1 4153/4885CYP3A4 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.